Yes, a 52-year-old who is non-immune to hepatitis B should absolutely be vaccinated.
Based on the 2022 ACIP guidelines, universal hepatitis B vaccination is now recommended for ALL adults aged 19-59 years, regardless of risk factors 111. Your 52-year-old patient falls squarely within this age range and should receive the vaccine series.
Why This Recommendation Changed
The shift from risk-based to universal vaccination for this age group addresses a critical public health gap. Previous guidelines required providers to screen for risk factors and patients to disclose them—an approach that resulted in suboptimal vaccination coverage 2. The universal recommendation removes these barriers and simplifies clinical practice: if the patient is 19-59 years old and lacks immunity, vaccinate them.
Key Clinical Points
No risk factor assessment is needed for this patient. The 2022 ACIP guidelines explicitly state that all adults aged 19-59 years should receive hepatitis B vaccination 11. This represents a fundamental change in approach—you no longer need to identify specific risk factors to justify vaccination in this age group.
The evidence supporting this change is robust:
- Modeling data showed that increased vaccination coverage in the 19-59 age group results in better health outcomes, including more quality-adjusted life years gained, life-years gained, acute HBV infections averted, and hepatitis B-related deaths averted 1
- Universal vaccination is cost-effective in this age group, with estimates around $36,000 per QALY gained 1
Practical Implementation
Vaccination schedule options 1:
- Standard 3-dose series (Recombivax HB or Engerix-B): 0,1, and 6 months
- 2-dose series (Heplisav-B): 0 and 1 month
- 3-dose series (PreHevbrio): 0,1, and 6 months
Important consideration for age 52: While vaccine response remains good in this age range, immunogenicity does decline with advancing age. Studies show seroprotection rates remain ≥80% up to age 60 3. Your patient at age 52 should still achieve excellent protection, with expected seroprotection rates around 82% for the 50-64 age group 4.
Common Pitfalls to Avoid
Don't delay vaccination while searching for documentation of previous doses. Only accept dated records as evidence of prior vaccination 1. Self-report alone is insufficient.
Don't order pre-vaccination testing unless the patient population has a high rate of previous HBV infection 1. Testing can be performed concomitantly with the first vaccine dose if cost is a concern, but lack of access to testing should never be a barrier to vaccination.
Don't skip post-vaccination serology in this patient. While not universally required, checking anti-HBs levels 1-2 months after series completion can confirm adequate response, particularly given the patient's age (52 years) where response rates begin to decline slightly 34.
Bottom Line
Vaccinate this patient now. The recommendation is clear, universal, and evidence-based for all adults aged 19-59 years who lack immunity 1115. This approach prevents acute hepatitis B infections, reduces chronic disease burden, and ultimately decreases hepatitis B-related mortality.